Literature DB >> 1287120

Expression, regulation and function of human Fc epsilon RII (CD23) antigen.

M Sarfati1, S Fournier, C Y Wu, G Delespesse.   

Abstract

CD23, also known as the low affinity receptor for IgE (Fc epsilon RII), belongs to a novel superfamily of type-II integral membrane proteins. Fc epsilon RII expression was originally described on B cells but subsequent studies showed that CD23 is expressed on a variety of hematopoietic cells and is regulated by several cytokines (i.e., interleukin-4, interferons) in a tissue-specific manner. In some pathological conditions such as B-chronic lymphocytic leukemia, the CD23 gene is abnormally regulated resulting in CD23 overexpression. CD23 is not only an IgE receptor but also a membrane-bound precursor of soluble molecules that still bind IgE (sCD23 or IgE-binding factors). The functions of membrane CD23 are IgE-dependent and vary according to the cell types on which it is expressed. In contrast, sCD23, in addition to being an IgE regulatory molecule, displays multiple cytokine activities that are IgE-independent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287120     DOI: 10.1007/bf02919132

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  96 in total

1.  Control of human B-lymphocyte replication. I. Characterization of novel activation states that precede the entry of G0 B cells into cycle.

Authors:  L Walker; G Guy; G Brown; M Rowe; A E Milner; J Gordon
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

2.  Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia.

Authors:  M Sarfati; D Bron; L Lagneaux; C Fonteyn; H Frost; G Delespesse
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

3.  Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells.

Authors:  T Defrance; B Vanbervliet; I Durand; J Banchereau
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

4.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

Authors:  F Wang; C D Gregory; M Rowe; A B Rickinson; D Wang; M Birkenbach; H Kikutani; T Kishimoto; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  IgE receptors on human lymphocytes. III. Expression of IgE receptors on mitogen-stimulated human mononuclear cells.

Authors:  G Delespesse; M Sarfati; M Rubio-Trujillo; T Wolowiec
Journal:  Eur J Immunol       Date:  1986-09       Impact factor: 5.532

6.  Regulation of human IgE synthesis. I. Human IgE synthesis in vitro is determined by the reciprocal antagonistic effects of interleukin 4 and interferon-gamma.

Authors:  I Chrétien; J Pène; F Brière; R De Waal Malefijt; F Rousset; J E De Vries
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

7.  IgE: an immunoglobulin specialized in antigen capture?

Authors:  G C Mudde; T T Hansel; F C von Reijsen; B F Osterhoff; C A Bruijnzeel-Koomen
Journal:  Immunol Today       Date:  1990-12

8.  Characterization of Fc receptors for IgE on human alveolar macrophages.

Authors:  F M Melewicz; L E Kline; A B Cohen; H L Spiegelberg
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

9.  Expression of the Fc-receptor for IgE (Fc epsilon RII, CD23) on alveolar macrophages in extrinsic allergic alveolitis.

Authors:  A Pforte; G Breyer; J C Prinz; P Gais; G Burger; K Häussinger; E P Rieber; E Held; H W Ziegler-Heitbrock
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens.

Authors:  D Vercelli; H H Jabara; K Arai; R S Geha
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  8 in total

Review 1.  CD23/FcεRII: molecular multi-tasking.

Authors:  M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  The absence of the transcription activator TFE3 impairs activation of B cells in vivo.

Authors:  K Merrell; S Wells; A Henderson; J Gorman; F Alt; A Stall; K Calame
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 3.  CD23 shedding: requirements for substrate recognition and inhibition by dipeptide hydroxamic acids.

Authors:  R J Mayer; P L Flamberg; S R Katchur; B J Bolognese; D G Smith; A E Marolewski; L A Marshall; A Faller
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

4.  Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).

Authors:  C Ribbens; V Bonnet; M J Kaiser; B Andre; O Kaye; N Franchimont; D de Groote; Y Beguin; M G Malaise
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Immunodeficiency due to a unique protracted developmental delay in the B-cell lineage.

Authors:  A S Goldman; S E Miles; H E Rudloff; K H Palkowetz; F C Schmalstieg
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

6.  Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.

Authors:  M Todorovic; M Pavlovic; B Balint; N Kraguljac; B Mihaljevic; A Bogdanovic; I Elezovic; D Boskovic; M Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  CD23 (FcepsilonRII) release from cell membranes is mediated by a membrane-bound metalloprotease.

Authors:  A E Marolewski; D R Buckle; G Christie; D L Earnshaw; P L Flamberg; L A Marshall; D G Smith; R J Mayer
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

8.  Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis.

Authors:  Anjana Singh; Sebastiaan J Vastert; Berent J Prakken; Harald Illges
Journal:  Rheumatol Int       Date:  2011-02-17       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.